Skye Bioscience, Inc. — Director's Dealing 2021

Dec 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Skye Bioscience, Inc. (SKYE)
CIK: 0001516551
Period of Report: 2021-12-14

Reporting Person: DHILLON PUNIT (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-12-14	Common Stock	A	2000000	—	Acquired	3000000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-12-14	Stock Option (Right to Buy)	$0.058	A	3090000	Acquired	2031-12-14	Common Stock (3090000.0)	Direct

Footnotes

F1: Represents a restricted stock unit ("RSU") award that vests in three equal annual installments commencing on the first anniversary of the grant date. Upon a change in control of the Issuer, all of the RSUs will vest in full.

F2: Each RSU represents a contingent right to receive one share of the Issuer's common stock.

F3: The option vests 25% on the one year anniversary of the grant date and 1/48th monthly thereafter. Upon a change in control of the Issuer, 100% of the options will become fully vested.